1. Home
  2. MDWD vs FSP Comparison

MDWD vs FSP Comparison

Compare MDWD & FSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MDWD
  • FSP
  • Stock Information
  • Founded
  • MDWD 2000
  • FSP 1981
  • Country
  • MDWD Israel
  • FSP United States
  • Employees
  • MDWD 88
  • FSP N/A
  • Industry
  • MDWD Medicinal Chemicals and Botanical Products
  • FSP Real Estate Investment Trusts
  • Sector
  • MDWD Health Care
  • FSP Real Estate
  • Exchange
  • MDWD Nasdaq
  • FSP Nasdaq
  • Market Cap
  • MDWD 179.1M
  • FSP 160.3M
  • IPO Year
  • MDWD 2014
  • FSP N/A
  • Fundamental
  • Price
  • MDWD $16.60
  • FSP $1.64
  • Analyst Decision
  • MDWD Strong Buy
  • FSP
  • Analyst Count
  • MDWD 1
  • FSP 0
  • Target Price
  • MDWD $28.00
  • FSP N/A
  • AVG Volume (30 Days)
  • MDWD 72.0K
  • FSP 285.6K
  • Earning Date
  • MDWD 08-14-2024
  • FSP 11-05-2024
  • Dividend Yield
  • MDWD N/A
  • FSP 2.44%
  • EPS Growth
  • MDWD N/A
  • FSP N/A
  • EPS
  • MDWD N/A
  • FSP N/A
  • Revenue
  • MDWD $20,141,000.00
  • FSP $133,729,000.00
  • Revenue This Year
  • MDWD $30.16
  • FSP N/A
  • Revenue Next Year
  • MDWD $18.44
  • FSP $0.02
  • P/E Ratio
  • MDWD N/A
  • FSP N/A
  • Revenue Growth
  • MDWD N/A
  • FSP N/A
  • 52 Week Low
  • MDWD $7.10
  • FSP $1.47
  • 52 Week High
  • MDWD $24.00
  • FSP $2.72
  • Technical
  • Relative Strength Index (RSI)
  • MDWD 40.31
  • FSP 47.15
  • Support Level
  • MDWD $16.85
  • FSP $1.70
  • Resistance Level
  • MDWD $20.55
  • FSP $1.78
  • Average True Range (ATR)
  • MDWD 1.00
  • FSP 0.07
  • MACD
  • MDWD -0.24
  • FSP 0.00
  • Stochastic Oscillator
  • MDWD 6.62
  • FSP 30.77

About MDWD MediWound Ltd.

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

About FSP Franklin Street Properties Corp.

Franklin Street Properties Corp is a real estate investment trust. The company is focused on commercial real estate investments in office markets and currently operate in only one segment: real estate operations. The company's operations include rental income from real estate leasing, interest income from secured loans made on office properties, property dispositions, and fee income from asset/property management and development. Franklin Street markets Atlanta, Dallas, Denver, Houston, and Minneapolis.

Share on Social Networks: